227 related articles for article (PubMed ID: 28165633)
21. Tumor-Infiltrating Lymphocytes, Crohn's-Like Lymphoid Reaction, and Survival From Colorectal Cancer.
Rozek LS; Schmit SL; Greenson JK; Tomsho LP; Rennert HS; Rennert G; Gruber SB
J Natl Cancer Inst; 2016 Aug; 108(8):. PubMed ID: 27172903
[TBL] [Abstract][Full Text] [Related]
22. Relationship between immune checkpoint proteins, tumour microenvironment characteristics, and prognosis in primary operable colorectal cancer.
Al-Badran SS; Grant L; Campo MV; Inthagard J; Pennel K; Quinn J; Konanahalli P; Hayman L; Horgan PG; McMillan DC; Roxburgh CS; Roseweir A; Park JH; Edwards J
J Pathol Clin Res; 2021 Mar; 7(2):121-134. PubMed ID: 33338327
[TBL] [Abstract][Full Text] [Related]
23. Programmed Death Ligand-1 expression in stage II colon cancer - experiences from a nationwide populationbased cohort.
Eriksen AC; Sørensen FB; Lindebjerg J; Hager H; dePont Christensen R; Kjær-Frifeldt S; Hansen TF
BMC Cancer; 2019 Feb; 19(1):142. PubMed ID: 30755167
[TBL] [Abstract][Full Text] [Related]
24. The prognostic value of cancer stem-like cell markers SOX2 and CD133 in stage III colon cancer is modified by expression of the immune-related markers FoxP3, PD-L1 and CD3.
Miller TJ; McCoy MJ; Hemmings C; Bulsara MK; Iacopetta B; Platell CF
Pathology; 2017 Dec; 49(7):721-730. PubMed ID: 29102042
[TBL] [Abstract][Full Text] [Related]
25. Preoperative, biopsy-based assessment of the tumour microenvironment in patients with primary operable colorectal cancer.
Park JH; van Wyk H; McMillan DC; Edwards J; Orange C; Horgan PG; Roxburgh CS
J Pathol Clin Res; 2020 Jan; 6(1):30-39. PubMed ID: 31486287
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of tumour necrosis and host inflammatory responses in colorectal cancer.
Richards CH; Roxburgh CS; Anderson JH; McKee RF; Foulis AK; Horgan PG; McMillan DC
Br J Surg; 2012 Feb; 99(2):287-94. PubMed ID: 22086662
[TBL] [Abstract][Full Text] [Related]
27. Combination of microsatellite instability and BRAF mutation status for subtyping colorectal cancer.
Seppälä TT; Böhm JP; Friman M; Lahtinen L; Väyrynen VM; Liipo TK; Ristimäki AP; Kairaluoma MV; Kellokumpu IH; Kuopio TH; Mecklin JP
Br J Cancer; 2015 Jun; 112(12):1966-75. PubMed ID: 25973534
[TBL] [Abstract][Full Text] [Related]
28. The prognostic impact of primary tumour location in patients with stage II and stage III colon cancer receiving adjuvant therapy. A GISCAD analysis from three large randomised trials.
Cascinu S; Poli D; Zaniboni A; Lonardi S; Labianca R; Sobrero A; Rosati G; Di Bartolomeo M; Scartozzi M; Zagonel V; Pella N; Banzi M; Torri V
Eur J Cancer; 2019 Apr; 111():1-7. PubMed ID: 30797014
[TBL] [Abstract][Full Text] [Related]
29. Intratumoral stromal morphometry predicts disease recurrence but not response to 5-fluorouracil-results from the QUASAR trial of colorectal cancer.
Hutchins GGA; Treanor D; Wright A; Handley K; Magill L; Tinkler-Hundal E; Southward K; Seymour M; Kerr D; Gray R; Quirke P;
Histopathology; 2018 Feb; 72(3):391-404. PubMed ID: 28746977
[TBL] [Abstract][Full Text] [Related]
30. The impact of CpG island methylator phenotype and microsatellite instability on tumour budding in colorectal cancer.
Zlobec I; Bihl MP; Foerster A; Rufle A; Lugli A
Histopathology; 2012 Nov; 61(5):777-87. PubMed ID: 22803799
[TBL] [Abstract][Full Text] [Related]
31. The relationship between tumour budding, the tumour microenvironment and survival in patients with primary operable colorectal cancer.
van Wyk HC; Park JH; Edwards J; Horgan PG; McMillan DC; Going JJ
Br J Cancer; 2016 Jul; 115(2):156-63. PubMed ID: 27299960
[TBL] [Abstract][Full Text] [Related]
32. The Proportion of Tumour-Stroma in Metastatic Lymph Nodes is An Accurately Prognostic Indicator of Poor Survival for Advanced-Stage Colon Cancers.
Zengin M; Benek S
Pathol Oncol Res; 2020 Oct; 26(4):2755-2764. PubMed ID: 32696416
[TBL] [Abstract][Full Text] [Related]
33. Perineural Invasion Is a Prognostic but not a Predictive Factor in Nonmetastatic Colon Cancer.
Leijssen LGJ; Dinaux AM; Taylor MS; Deshpande V; Kunitake H; Bordeianou LG; Berger DL
Dis Colon Rectum; 2019 Oct; 62(10):1212-1221. PubMed ID: 31490830
[TBL] [Abstract][Full Text] [Related]
34. Prognostic role of tumour-infiltrating T lymphocytes in stage IIA (T3N0) colon cancer: A broad methodological study in a fairly homogeneous population.
Zengin M
Ann Diagn Pathol; 2019 Aug; 41():69-78. PubMed ID: 31146180
[TBL] [Abstract][Full Text] [Related]
35. Sidedness is prognostic in locoregional colon cancer: an analysis of 9509 Australian patients.
Brungs D; Aghmesheh M; de Souza P; Ng W; Chua W; Carolan M; Clingan P; Healey E; Rose J; Tubaro T; Ranson M
BMC Cancer; 2017 Apr; 17(1):251. PubMed ID: 28390415
[TBL] [Abstract][Full Text] [Related]
36. Better survival in right-sided versus left-sided stage I - III colon cancer patients.
Warschkow R; Sulz MC; Marti L; Tarantino I; Schmied BM; Cerny T; Güller U
BMC Cancer; 2016 Jul; 16():554. PubMed ID: 27464835
[TBL] [Abstract][Full Text] [Related]
37. A high tumour-stroma ratio (TSR) in colon tumours and its metastatic lymph nodes predicts poor cancer-free survival and chemo resistance.
Strous MTA; Faes TKE; Gubbels ALHM; van der Linden RLA; Mesker WE; Bosscha K; Bronkhorst CM; Janssen-Heijnen MLG; Vogelaar FJ; de Bruïne AP
Clin Transl Oncol; 2022 Jun; 24(6):1047-1058. PubMed ID: 35064453
[TBL] [Abstract][Full Text] [Related]
38. In reply to Hynes et al.: 'Back to the future: routine morphological assessment of the tumour microenvironment is prognostic in stages II/III colon cancer in a large population-based study'.
van Pelt GW; Huijbers A; Tollenaar RAEM; Mesker WE
Histopathology; 2018 Feb; 72(3):531-532. PubMed ID: 28898449
[No Abstract] [Full Text] [Related]
39. Comparison of visual and automated assessment of tumour inflammatory infiltrates in patients with colorectal cancer.
Forrest R; Guthrie GJ; Orange C; Horgan PG; McMillan DC; Roxburgh CS
Eur J Cancer; 2014 Feb; 50(3):544-52. PubMed ID: 24332571
[TBL] [Abstract][Full Text] [Related]
40. Microsatellite instability is associated with reduced disease specific survival in stage III colon cancer.
Mohan HM; Ryan E; Balasubramanian I; Kennelly R; Geraghty R; Sclafani F; Fennelly D; McDermott R; Ryan EJ; O'Donoghue D; Hyland JM; Martin ST; O'Connell PR; Gibbons D; Winter D; Sheahan K
Eur J Surg Oncol; 2016 Nov; 42(11):1680-1686. PubMed ID: 27370895
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
